Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Drug Resistance and Modifiers

Abstract C99: Wogonin enhanced reactive oxygen species-induced apoptosis and potentiated cytotoxic effects of chemotherapeutic agents by Nrf2 suppression in HepG2 cells.

Chen Qian and Rong Hu
Chen Qian
China Pharmaceutical University, Nanjing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rong Hu
China Pharmaceutical University, Nanjing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.TARG-13-C99 Published November 2013
  • Article
  • Info & Metrics
Loading

Abstract

Abstract: Cancer cells, compared to normal cells, are under increased oxidative stress with higher level of ROS. When exposed to environmental or intracellular stresses like ROS, NFE-related factor 2 (Nrf2) is the key to antioxidant response by transcriptionally activate various detoxification and antioxidant enzymes. We have previously shown that wogonin (5,7-Dihydroxy-8-methoxy-2-phenyl-4H-1-benzopyran-4-one), a flavonoid isolated from the root of Scutellaria baicalensis Georgi, could reverse drug resistance in MCF-7/ DOX cells through blocking the translocation of Nrf2 into nucleus, however, the effects of wogonin on Nrf2 signaling pathway have not previously been reported. In our study, we observed that wogonin reduced Nrf2 nuclear translocation, and therefore elevated the level of intracellular ROS to accomplish the purpose of killing malignant cells. In order to confirm the roles of Nrf2, it was activated by tBHQ and knocked down by the Nrf2 siRNA, and the results demonstrated that the activation of Nrf2 was involved in the wogonin-induced accumulation of ROS and cell death. Furthermore, the suppression of Nrf2 by wogonin can potentiate cytotoxic effects of chemotherapeutic agents in HepG2 cells. On one hand, down-regulation of Nrf2 lead to reduction of cytoprotective effect through inducing phage II enzymes which sensitize cells to chemotherapeutic agents. On the other hand, inhibition of multidrug resistance-associated protein (MRPs) by wogonin to enhance the effective drug level in cancer cells is another way to potentiates chemotherapeutic effects. At last, we found that the down-regulation of Nrf2 is associated with over-expression of p53. Using p53 siRNA to knock down the endogenous p53 expression, the level of both c-Myc and Nrf2 in nucleus increased when exposed to wogonin. The present study indicated that wogonin can be used in chemotherapy not only because its own antitumor ability, but also due to the enhanced cytotoxic effects of chemotherapeutic agents.

Citation Information: Mol Cancer Ther 2013;12(11 Suppl):C99.

Citation Format: Chen Qian, Rong Hu. Wogonin enhanced reactive oxygen species-induced apoptosis and potentiated cytotoxic effects of chemotherapeutic agents by Nrf2 suppression in HepG2 cells. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr C99.

  • Copyright © November 2013, American Association for Cancer Research
Previous
Back to top
Molecular Cancer Therapeutics: 12 (11 Supplement)
November 2013
Volume 12, Issue 11 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract C99: Wogonin enhanced reactive oxygen species-induced apoptosis and potentiated cytotoxic effects of chemotherapeutic agents by Nrf2 suppression in HepG2 cells.
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract C99: Wogonin enhanced reactive oxygen species-induced apoptosis and potentiated cytotoxic effects of chemotherapeutic agents by Nrf2 suppression in HepG2 cells.
Chen Qian and Rong Hu
Mol Cancer Ther November 1 2013 (12) (11 Supplement) C99; DOI: 10.1158/1535-7163.TARG-13-C99

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract C99: Wogonin enhanced reactive oxygen species-induced apoptosis and potentiated cytotoxic effects of chemotherapeutic agents by Nrf2 suppression in HepG2 cells.
Chen Qian and Rong Hu
Mol Cancer Ther November 1 2013 (12) (11 Supplement) C99; DOI: 10.1158/1535-7163.TARG-13-C99
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Drug Resistance and Modifiers

  • Abstract LB-A11: Quantitative and qualitative characterization of spontaneous resistance to targeted protein degradation
  • Abstract LB-A10: ORIC-101 overcomes glucocorticoid-driven resistance to enzalutamide in castration-resistant prostate cancer
  • Abstract LB-A12: A synthetic lethal drug screen identifies exploitable vulnerabilities in cohesin-deficient cells
Show more Drug Resistance and Modifiers

Drug Resistance and Modifiers: Poster Presentations - Proffered Abstracts

  • Abstract LB-A11: Quantitative and qualitative characterization of spontaneous resistance to targeted protein degradation
  • Abstract LB-A10: ORIC-101 overcomes glucocorticoid-driven resistance to enzalutamide in castration-resistant prostate cancer
  • Abstract LB-A12: A synthetic lethal drug screen identifies exploitable vulnerabilities in cohesin-deficient cells
Show more Drug Resistance and Modifiers: Poster Presentations - Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement